CAMBRIDGE, Mass., September 25, 2024--2seventy bio, Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with ...

There was a lot to cheer outside Enterprise Center Tuesday morning. Riders ready to brave their bikes with the St. Louis ...

An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...

Shares of Bristol Myers Squibb Co. BMY rallied 1.86% to $50.94 Tuesday, on what proved to be an all-around favorable trading ...

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) shares are trading lower by 4.11% to $15.62 during Tuesday’s session after the ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Biomedicines and its artificial intelligence platform to generate drugs for multiple undisclosed targets. Generate will receive $65 million up front, which includes an equity investment of $15 million ...

After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.

US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...

Several studies revealed high cardiovascular risk in people with type 1 diabetes, including in those who are asymptomatic and ...

Delayed diagnosis and treatment of CCCA result in insufficiently aggressive therapy and risks an avoidable consequence, ...

More than 75% of the cohort started a TNF inhibitor during the selected time frame. For the rest, JAK inhibitors were the ...